Table 1.
Baseline characteristics and outcome of patients who did or did not receive MST treatment
| Characteristics | MST | NonMST | P-value |
|---|---|---|---|
| N | 64.00 | 64.00 | |
| Age, years | 39.61±17.14 | 41.01±16.38 | 0.767 |
| Sex (% male) | 53.00 (82.81) | 51.00 (79.68) | 0.325 |
| APACHE II score AD | 21.81±2.75 | 21.61±2.44 | 0.677 |
| Glucose, mmol/L AD | 10.60±1.71 | 10.25±1.40 | 0.208 |
| NSE, g/L AD | 32.76±6.88 | 33.12±6.13 | 0.756 |
| NSE, g/L after 3 days | 28.93±6.50 | 32.11±7.09 | 0.100 |
| NSE, g/L after 7 days | 25.40±6.66 | 29.58±7.32 | 0.001 |
| GCS AD | 5.82±1.71 | 5.36±1.91 | 0.159 |
| GCS after 3 days | 7.39±2.07 | 6.23±2.29 | 0.004 |
| GCS after 7 days | 8.23±2.72 | 7.05±2.64 | 0.016 |
| GOS at discharge | 3.30±1.35 | 3.96±1.10 | 0.004 |
| GOS after 3 months | 2.95±1.48 | 3.66±1.44 | 0.009 |
| The events at discharge | 46 (70.31) | 52 (81.25) | 0.149 |
| The events after 3 months | 35 (54.69) | 51 (79.69) | 0.001 |
| ICU duration, days | 21.04±9.39 | 23.67±14.59 | 0.231 |
| ICU mortality (%) | 20 (31.25) | 26 (40.62) | 0.167 |
Notes: Events. GOS of patients were III, IV, and V (the poor prognosis group). P-value of <0.05 was considered as significant.
Abbreviations: AD, admission; APACHE, acute physiologic score and chronic health evaluation; GCS, Glasgow coma scale; GOS, Glasgow outcome scale; ICU, intensive care unit; MST, magnesium sulfate treatment; NSE, neuron-specific enolase.